Ling Huang
Has grant
Assistant Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
investigate therapeutic potentials of EZH2 targeting in pancreatic cancer using patient derived organoids
Open Date:
Close Date:
Grant: Close
Circulating tumor cells for predicting pancreatic cancer patient responses to chemotherapies
Open Date:
Close Date:
Articles (8)
Cancer immunology-related molecular features of tumors from BAA and White patients. A and B, TMB of tumors from BAA (purple) and White (orange) patients. B, TMBs in patients stratified by race and sex. C, TMB of tumors from BAA (purple) and White (orange) patients at different clinical stages. D, Percentage of PD-L1 positive patients in BAA (purple) and White (orange) groups. E, Percentage of PD-L1 positive BAA (purple) and White (orange) patients at different clinical stages. The significance of differences between groups was calculated by Fisher’s exact test or χ 2 test. Significance representation: N.S., P ≥ 0.05; *, 0.01 ≤ P P
Year:
2025
TP53 and KRAS mutations in BAA and White patients from cohorts in AACR Project GENIE. A and B, frequencies of TP53 genomic alterations in BAA (purple) and White (orange) patients from MSK ( A ) and DFCI ( B ). C and D, frequencies of KRAS G12R in BAA (purple) and White (orange) patients from Memorial Sloan Kettering Cancer Center (MSK, C ) and (DFCI, D ). P value indicators: N.S., P ≥ 0.05; *, 0.01 ≤ P
Year:
2025
Genomic alterations in BAA and White patients with pancreatic ductal adenocarcinoma. A, Percentage of patients with genomic changes in specific genes (row name). Q values represent adjusted P values after FDR correction. B, Distributions of KRAS mutant alleles in patients with pancreatic cancer. The “other” group includes wild-type KRAS and all other mutations that are not G12D, G12V, G12R, Q61H, or G12C. C and D, Association between KRAS mutants and KMT2C/D mutants, respectively. The number and colors represent percentages of patients with KMT2C or KMT2D mutations in specific KRAS mutant groups (Y) and the rest of patients (N). Column names represent the specific KRAS mutant alleles analyzed. The significance of differences between groups was calculated by Fisher’s exact test or χ 2 test. Significance representation: N.S., P ≥ 0.05; **, 0.001 ≤ P P
Year:
2025
Pancreatic cancer is the third leading cause of cancer-related death in the United States. Black or African American patients have a higher incidence of pancreatic cancer compared with other racial groups. It is unclear whether distinct molecular mechanisms are involved in the development of pancreatic cancer in different racial groups. To identify tumor molecular features that are distinctly associated with race in Black or African American and White patients with pancreatic ductal adenocarcinoma (the main subtype of pancreatic cancer), we analyzed deidentified patient records, including tumor sequencing data and expression of PD-L1, from the Tempus multimodal database. Patients with a primary diagnosis of pancreatic ductal adenocarcinoma and who received molecular testing between November 2017 and March 2023 were included in analyses. Among 4,249 patients analyzed in this study, 452 (10.6%) were Black or African American, and 3,797 (89.4%) were White. Black patients had a higher prevalence of TP53 mutations compared with White patients ( P KRAS G12R mutations occurred more frequently in female patients in the Black versus White group ( P = 0.007). Compared with White patients, Black patients had a higher tumor mutational burden ( P P = 0.047). In a separate analysis of recent clinical trials testing immunotherapies for pancreatic cancer, we found that Black patients and other minorities were underrepresented in most trials. These findings suggest race-associated molecular differences in tumors that may impact patient responses to immunotherapies. Our study also supports the importance of improving patient diversity in clinical trials on pancreatic cancer treatments. Significance: By analyzing the records of patients with pancreatic cancer in the Tempus multimodal database, we identified genomic mutations and PD-L1 overexpression occurred more frequently in Black patients compared with their White counterparts. These molecular features may contribute to racial disparities in pancreatic cancer.
Year:
2025
Cellular plasticity is a hallmark of pancreatic ductal adenocarcinoma (PDAC) starting from the conversion of normal cells into precancerous lesions, to the progression of carcinoma subtypes associated with aggressiveness and therapeutic response. We discovered that normal acinar cell differentiation, maintained by the transcription factor PDX1, suppresses a broad gastric cell identity that is maintained in metaplasia, neoplasia, and the classical subtype of PDAC in a mouse and human. We identified the receptor tyrosine kinase ROR2 as marker of a gastric metaplasia-like identity in pancreas neoplasms. Ablation of Ror2 in a mouse model of pancreatic tumorigenesis promoted a switch to a gastric pit cell identity that largely persisted through progression to the classical subtype of PDAC. In both human and mouse pancreatic cancer, ROR2 activity continued to antagonize the gastric pit cell identity, strongly promoting an epithelial to mesenchymal transition, conferring resistance to KRAS inhibition, and vulnerability to AKT inhibition. Significance: We discovered the receptor tyrosine kinase ROR2 as an important regulator of cellular identity in pancreatic precancerous lesions and pancreatic cancer. ROR2 drives an aggressive PDAC phenotype and confers resistance to KRAS inhibitors, suggesting that targeting ROR2 will enhance sensitivity to this new generation of targeted therapies. See related commentary by Marasco and Misale, p. 2018
Year:
2024
Ductal and acinar pancreatic organoids are promising models for the study of pancreatic diseases. Genome sequencing studies have revealed that mutations in a G-protein ( GNAS R201C ) are exclusively observed in intraductal papillary mucinous neoplasms (IPMN). The biological mechanisms by which GNAS R201C affects the ductal and acinar exocrine pancreas are unclear. Here, we use human stem-cell-derived pancreatic ductal and acinar organoids and demonstrate that GNAS R201C was more effective in inducing proliferation in ductal organoids compared with acinar organoids. Surprisingly, GNAS R201C -induced cell proliferation was protein kinase A (PKA)-independent in ductal organoids and an immortalized ductal epithelial cell line. Co-expression of oncogenic KRASG12V and GNAS R201C retained PKA-independence in ductal organoids to stimulate cell proliferation. Thus, we identify cell lineage-specific roles for PKA signaling in GNAS R201C -driven cell proliferation in precancerous lesions and report the development of a human pancreatic ductal organoid model system to investigate mechanisms regulating GNAS R201C -induced IPMNs. Implications: The study identifies an opportunity to discover a PKA-independent pathway downstream of oncogene GNAS for managing IPMN lesions and their progression to PDAC.
Year:
2024
Ductal and acinar pancreatic organoids are promising models for the study of pancreatic diseases. Genome sequencing studies have revealed that mutations in a G-protein ( GNAS R201C ) are exclusively observed in intraductal papillary mucinous neoplasms (IPMN). The biological mechanisms by which GNAS R201C affects the ductal and acinar exocrine pancreas are unclear. Here, we use human stem-cell-derived pancreatic ductal and acinar organoids and demonstrate that GNAS R201C was more effective in inducing proliferation in ductal organoids compared with acinar organoids. Surprisingly, GNAS R201C -induced cell proliferation was protein kinase A (PKA)-independent in ductal organoids and an immortalized ductal epithelial cell line. Co-expression of oncogenic KRASG12V and GNAS R201C retained PKA-independence in ductal organoids to stimulate cell proliferation. Thus, we identify cell lineage-specific roles for PKA signaling in GNAS R201C -driven cell proliferation in precancerous lesions and report the development of a human pancreatic ductal organoid model system to investigate mechanisms regulating GNAS R201C -induced IPMNs. Implications: The study identifies an opportunity to discover a PKA-independent pathway downstream of oncogene GNAS for managing IPMN lesions and their progression to PDAC.
Year:
2024
Ductal and acinar pancreatic organoids are promising models for the study of pancreatic diseases. Genome sequencing studies have revealed that mutations in a G-protein (GNASR201C) are exclusively observed in intraductal papillary mucinous neoplasms (IPMN). The biological mechanisms by which GNASR201C affects the ductal and acinar exocrine pancreas are unclear. Here, we use human stem-cell-derived pancreatic ductal and acinar organoids and demonstrate that GNASR201C was more effective in inducing proliferation in ductal organoids compared with acinar organoids. Surprisingly, GNASR201C-induced cell proliferation was protein kinase A (PKA)-independent in ductal organoids and an immortalized ductal epithelial cell line. Co-expression of oncogenic KRASG12V and GNASR201C retained PKA-independence in ductal organoids to stimulate cell proliferation. Thus, we identify cell lineage-specific roles for PKA signaling in GNASR201C-driven cell proliferation in precancerous lesions and report the development of a human pancreatic ductal organoid model system to investigate mechanisms regulating GNASR201C-induced IPMNs. Implications: The study identifies an opportunity to discover a PKA-independent pathway downstream of oncogene GNAS for managing IPMN lesions and their progression to PDAC.
Year:
2024
Collaborators (6)
Jonathan Preall
Research Associate Professor
Cold Spring Harbor Laboratory
Howard Crawford
Professor
University of Michigan
Senthil K Muthuswamy
Chief
National Cancer Institute
Filip Bednar
University of Michigan
Raul S. Gonzalez
Emory University Hospital
Nina Steele
Assistant Professor
University of Cincinnati
Make your next move.
Prepare your application
Review drafts before you send them.